Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) and Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.
Volatility & Risk
Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.
Profitability
This table compares Kymera Therapeutics and Werewolf Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kymera Therapeutics | -611.94% | -24.71% | -22.05% |
| Werewolf Therapeutics | N/A | -208.23% | -75.12% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kymera Therapeutics | $39.21 million | 208.64 | -$311.35 million | ($3.57) | -27.86 |
| Werewolf Therapeutics | $1.88 million | 9.57 | -$60.82 million | ($1.24) | -0.30 |
Werewolf Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for Kymera Therapeutics and Werewolf Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kymera Therapeutics | 1 | 0 | 21 | 1 | 2.96 |
| Werewolf Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
Kymera Therapeutics presently has a consensus price target of $117.14, suggesting a potential upside of 17.78%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 913.24%. Given Werewolf Therapeutics’ higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Kymera Therapeutics.
Institutional and Insider Ownership
64.8% of Werewolf Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Kymera Therapeutics beats Werewolf Therapeutics on 8 of the 15 factors compared between the two stocks.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
